Company focused on editing the human leukocyte antigen (HLA) to transform autoimmunity Lead program, RG0401, in development for treatment-resistant or…
Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab’s antibody discovery platform. CAMBRIDGE,…